Oligonucleotide Synthesis Market CAGR 9.9% by 2035, Due To The Growing Demand For Oligonucleotide Therapeutics | Roots Analysis

According to our latest market report "Oligonucleotide Synthesis Market by Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-users, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the global oligonucleotide synthesis market size is projected to reach USD 13.5 billion by 2035 from USD 4.8 billion in 2024, growing at a CAGR of 9.9% in the forecast period 2024-2035.

Oligonucleotides (commonly referred to as oligos) are short single stranded DNA or RNA molecules, typically comprising of 15-20 nucleotide residues. These molecules are widely used in biopharmaceutical and biotechnology industries for a wide range of applications, including research and genetic testing, forensic analysis and other analytical procedures. Presently, researchers are actively exploring the use of oligonucleotides as a pharmacological intervention, for the treatment of a myriad of disease indications. Given the advancement of several promising oligonucleotide therapeutics through clinical pipeline, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/request-quote.html

Oligonucleotide Synthesis Market Segments
Based on the application area, the market is segmented into research and diagnostics, and therapeutics.
1. The research and diagnostics segment led the oligonucleotide synthesis market, capturing the largest revenue share of 59% in 2024.
2. Therapeutics segment is anticipated to witness the highest market growth rate of 9.9%, annually during the forecast period.

Based on the type of product synthesized, the market is segmented into active pharmaceutical ingredients and finished dosage forms.

1. The Active Pharmaceutical Ingredients segment led the oligonucleotide synthesis market, capturing the largest revenue share of 62% in 2024.
2. The Finished Dosage Forms segment is anticipated to witness the highest market growth rate of 9.9%, annually during the forecast period.

Based on the type of oligonucleotide synthesized, the market is segmented into antisense, siRNA, DNA and others.

1. The antisense oligonucleotides segment led the oligonucleotide synthesis market, capturing the largest revenue share of close to 63% in 2024.
2. Both DNA and siRNA segments are anticipated to witness the highest market growth rate of 10.2%, annually during the forecast period.

Based on the scale of operation, the market is segmented into clinical and commercial.

1. The commercial scale of operation segment has led the oligonucleotide synthesis market, capturing the largest revenue share of 80% in 2024.
2. Clinical scale segment is anticipated to witness the highest market growth rate of 12.3%, annually during the forecast period.

Based on the therapeutic area, the market is segmented into cardiovascular disorders, genetic disorders, liver disorders, rare diseases and other disorders.

1. The rare diseases segment led the oligonucleotide synthesis market, capturing the largest revenue share of close to 43% in 2024.
2. Cardiovascular, genetic and liver disorders segments are anticipated to witness the highest market growth rate of 10.2%, each during the forecast period.

Based on the end-users, the market is segmented into pharmaceutical / biopharmaceutical companies, academic and research institutes and hospitals.

1. The pharmaceutical / biopharmaceutical companies segment led the oligonucleotide synthesis market, capturing the largest revenue share of around 65% in 2024.
2. In fact, both pharmaceutical / biopharmaceutical companies, and academic and research institutes segments are anticipated to witness the highest market growth rate of 10.0%, annually during the forecast period.

Based on the company size, the market is segmented into small companies, mid-sized companies, and large and very large companies.

1. The large and very large companies segment led the oligonucleotide synthesis market, capturing the largest revenue share of around 75% in 2024.
2. The mid-sized companies segment is anticipated to witness the highest market growth rate of 14.1%, annually during the forecast period.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/request-sample.html

Based on the Regional Insights, the market is segmented into North America, Europe, and Asia-Pacific and Rest of the World

1. North America dominated the oligonucleotide synthesis market and accounted for the largest revenue share of about 45% in 2024.
2. In Asia-Pacific, the oligonucleotide synthesis market is anticipated to demonstrate lucrative growth during the forecast period.

Oligonucleotide Synthesis Market Regional Outlook
Based on the key geographical regions, the oligonucleotide synthesis market can be segmented into four major regions, including North America, Europe, Asia Pacific and rest of the world. Led by the US, North America is anticipated to capture the majority share of the oligonucleotide synthesis market in 2024. The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the manufacturing market in this region is primarily driven by technical advancements, rise in skilled population, low labor costs and socio-economic regulatory reforms favoring the growth of the microbiome industry.

Key Report Takeaways
1. Presently, over 110 synthesis providers (established as well as startups) claim to have the necessary capabilities to offer oligonucleotide synthesis services; majority of these firms are based in North America
2. Stakeholders in this domain synthesize various types of oligonucleotides, across different scales of operations; close to 90% of the players offer purification services
3. In pursuit of building a competitive edge in this field, stakeholders are actively upgrading their existing
4. capabilities and adding new competencies in order to enhance their respective portfolios
5. Close to 300 clinical trials (with over 75,000 enrolled patients) have been registered to investigate oligonucleotide based-therapeutic products, across different geographies
6. Since 2017, more than 55 deals have been inked between various stakeholders engaged in this domain; acquisitions emerged as the most common type of partnership model
7. To keep pace with the growing demand for oligonucleotides, companies have made elaborate investments to expand their existing capacities and capabilities; this trend is most pronounced in the US and China
8. Several big pharma players have undertaken various initiatives, including partnerships, expansions and funding initiatives; 48% of such initiatives were focused on the development and manufacturing of RNAi oligonucleotides
9. The global, installed oligonucleotide synthesis capacity is spread across various geographies; interestingly, more than 75% of the total capacity is installed at the facilities owned by large and very large players
10. Given the growing complexity of APIs, the demand for oligonucleotides has upsurged; by 2035, it is anticipated to reach around 2,200 kilograms, across clinical and commercial scales
11. Considering the wide array of applications of oligonucleotides and continuous research efforts of stakeholders in this domain, the adoption of these modalities is poised to witness a steady growth in foreseeable future
12. Driven by the increasing number of chronic indications (requiring novel personalized therapies), and ongoing research on oligonucleotide-based therapeutics, this market is anticipated to grow at a CAGR of 9.9%, till 2035
13. Over 40% of the market is expected to be captured by revenues generated from manufacturing drugs for rare diseases; further, oligonucleotide synthesis market in China is likely to grow at a faster pace.

Oligonucleotide Synthesis Market Key Players
Examples of key companies engaged in oligonucleotide synthesis market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Merck, Thermo Fisher Scientific and TriLink BioTechnologies.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.